Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 First-in-human Study of BGM-2121 in Patients With Advanced Solid Tumors

NCT07346846 is registered in ClinicalTrials.gov with BioGate Precision Medicine Corp. as lead sponsor.

NCT NCT07346846
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07346846 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 First-in-human Study of BGM-2121 in Patients With Advanced Solid Tumors
Lead sponsor
BioGate Precision Medicine Corp.
Phase
Phase 1
Overall status
Recruiting
Start date
March 10, 2026
Completion date
December 31, 2028
Enrollment
35 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors